Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome (OBEMINALE2)

• ClinicalTrials.gov Identifier: NCT03692806
• Recruitment Status: Completed
• First Posted: October 2, 2018
• Last Update Posted: December 17, 2020
• Sponsor: LNC THERAPEUTICS
• Collaborators: Biofortis Mérieux NutriSciences; StatistiCal BV Wassenarr, The Netherland represented by Dr W.Calame
• Information provided by (Responsible Party): YSOPIA Bioscience ( LNC THERAPEUTICS )

Study Description

Brief Summary:

The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.

Condition or disease	Intervention/treatment	Phase
Metabolic Syndrome	Dietary Supplement: Stablor; Dietary Supplement: placebo	Not Applicable

Detailed Description:

It is expected that the food product STABLOR will reduce visceral fat mass in subjects with metabolic syndrome and therefore will improve cardiometabolic risk factors. The aim of the current study is to assess the impact of a 12-week intake of STABLOR, compared to a placebo, on visceral fat in patients with metabolic syndrome. The primary objective of the study is to assess the efficacy of 12-week STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome. The Secondary outcomes include Anthropometric measurements and body composition, metabolic syndrome status, STABLOR® metabolism, Cardiovascular biomarkers, Systemic inflammation, Quality of life and Behavior.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 240 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A 3-month Randomized Double Blind Placebo-controlled Multicenter Study to Assess the Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
• Actual Study Start Date: September 11, 2018
• Actual Primary Completion Date: October 31, 2019
• Actual Study Completion Date: December 16, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Stablor; 2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks	Dietary Supplement: Stablor; Stablor sachet
Placebo Comparator: placebo; 2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks	Dietary Supplement: placebo; placebo sachet

Outcome Measures

Primary Outcome Measures :

1. Absolute change of visceral fat mass (in cubic millimeter) assessed by Magnetic Resonance Imaging [ Time Frame: between week 0, week 9, week 12 ]

Secondary Outcome Measures :

1. Change of visceral fat mass in percentage assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
2. Changes of total abdominal fat mass in cubic millimeter assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
3. Changes of subcutaneous fat mass in cubic millimeter assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
4. Changes of total abdominal fat mass in percentage assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
5. Changes of subcutaneous fat mass in percentage assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
6. Changes of body fat mass measured by Dual-energy X-ray absorptiometry [ Time Frame: between Week 0 and Week 12 ]
7. Changes of body lean mass measured by Dual-energy X-ray absorptiometry [ Time Frame: between Week 0 and Week 12 ]
8. Changes of trunk fat assessed by Dual-energy X-ray absorptiometry [ Time Frame: between Week 0 and Week 12 ]
   calculated trunk fat
9. Changes of anthropometrics measurements : weight [ Time Frame: between Week 0 and Week 12 ]
   Weight
10. Changes of anthropometrics measurements : BMI [ Time Frame: between Week 0 and Week 12 ]
    BMI
11. Changes of anthropometrics measurements: Waist circumference [ Time Frame: between Week 0 and Week 12 ]
    Waist Circumference
12. Changes of anthropometrics measurements: Hip Circumference [ Time Frame: between Week 0 and Week 12 ]
    Hip Circumference
13. Changes of anthropometrics measurements: Waist to Hip ratio [ Time Frame: between Week 0 and Week 12 ]
    Waist to Hip ratio
14. Changes of anthropometrics measurements: Waist to Height ratio [ Time Frame: between Week 0 and Week 12 ]
    Waist to Height ratio

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Female or male
• Age between 18 and 65 years (limits included),
• BMI between 27 and 40 kg/m² (limits included),

• With metabolic syndrome: Waist circumference > 94 cm for male (>90 cm for male of South-East Asian, Chinese and Japanese ethnic groups) and > 80 cm for female and at least two of the following criteria :

  • Triglycerides levels ≥ 1.5 g/L (1.71 mmol/L) or stable under treatment for at least 6 months,
  • HDL cholesterol levels <0.40 g/L (1.03 mmol/L) for male and <0.5 g/l (1.29 mmol/L) for female or stable under treatment for at least 6 months,
  • Fasting plasma glucose ≥1 g/L (5.6 mmol/L) and non-diabetic,
  • Blood pressure ≥130 mmHg (systolic) and/or 85 mmHg (diastolic) or stable under antihypertensive treatment for at least 6 months,
• Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,
• Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,

Exclusion Criteria:

• Suffering from a metabolic disorder such as diabetes uncontrolled thyroidal trouble or other metabolic disorder,
• Suffering from a cardiac insufficiency, inflammatory disease, severe hepatic of renal insufficiency, or gastrointestinal disorders (Crohn's disease or Ulcerative Colitis) or others diseases found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease),
• Having suffered of stroke or ictus within the last 6 months,
• Suffering of depression,
• Had a major surgical procedure within the last 6 months,
• Had a bariatric surgery,
• With a known or suspected food allergy or intolerance to lactose or soja, or hypersensitivity to any of the study products' ingredient,
• Who does not like the investigational product flavors "vanilla-toffee", "chocolate" and "coffee",
• Having a biological selection profile considered as abnormal by the investigator (BUN, Creatinine, calcium, Liver enzymes (GGT, AST, ALT), Blood Cell Count, , HIV, HCV, lipids (TG, HDL, LDL, total cholesterol),glycaemia, B HCG),
• Pregnant (positive pregnancy test at selection visit) or lactating women or intending to become pregnant within 6 months ahead,
• Women of child bearing potential without efficient contraception,
• Under nutritional supplement or drugs acting on weight or satiety according to the investigator or stopped less than 6 months before the study,
• With a current or planned in the next 6 months specific diet (hypocaloric, vegan, vegetarian…) or stopped less than 6 months before the study,
• Treated with drugs acting on visceral fat mass &inflammation : corticosteroids, neuroleptics, alpha et beta blockers, anti-HIV tritherapy, anti-TNF alpha, antidepressant or anticoagulating agents,
• Treated with antibiotics in the 3 months prior to selection,
• With significant change in food habits or in physical activity in the 6 months before the V0 visit,
• With significant changes in lipid abnormality of antihypertensive treatment within 3 months prior to selection,
• With a personal history of bulimia or significant eating disorders according to the investigator,
• Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
• Consuming tobacco more than 10 mg of nicotine per day
• Consuming drugs,
• Patients who suffer from claustrophobia,
• Patients who have contraindications to perform an MRI such as pacemakers, intracranial clips incompatible with MRI, heart valves, hearing aid,... and other types of implants incompatible with MRI,
• Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
• Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
• Presenting a psychological or linguistic incapability to sign the informed consent,
• Impossible to contact in case of emergency.

Contacts and Locations

Locations

France

CEN Experimental

Dijon, France, 21000

Eurofins Optimed

Gières, France, 38610

Institut Pasteur de Lille

Lille, France, 59019

CIC Pitié Salpêtrière

Paris, France, 75651

Biofortis

Saint Herblain, France, 44800

Ireland

Atlantia Food Clinical Trials

Cork, Ireland

Sponsors and Collaborators

LNC THERAPEUTICS

Biofortis Mérieux NutriSciences

StatistiCal BV Wassenarr, The Netherland represented by Dr W.Calame

Investigators

• Principal Investigator: Marie Déciron, MD; BioFortis

More Information

• Responsible Party: LNC THERAPEUTICS
• ClinicalTrials.gov Identifier: NCT03692806
• Other Study ID Numbers: 2018-A01402-53
• First Posted: October 2, 2018
• Last Update Posted: December 17, 2020
• Last Verified: December 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Metabolic Syndrome; Syndrome; Disease; Pathologic Processes; Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases